Location Boston, Massachusetts, United States Regions Greater Boston Area, East Coast, New England Gender Male
LinkedIn View on LinkedIn
Mark A. Tepper, Ph.D., co-founded the Company in 2009. He has more than twenty years of leadership experience in pharmaceutical R&D and his past roles include leadership positions at Bristol Myers Squibb, Serono, CytRx, RXi Pharmaceuticals and NKT Therapeutics. Dr. Tepper has led teams in the discovery and development of a number of
r of first-in-class drugs, including Guspermis, Taxol, Rebif, Orcenia and Gonal-F. During the last 10 years Dr. Tepper has focused his career on identifying unique early stage biotechnology assets, which fill a significant unmet medical need and forming companies to commercialize these assets. In this role, he has successfully founded and developed the commercialization strategy for 3 new biotech companies, raising over $45M in funding. Dr. Tepper received a Ph.D. in Biochemistry & Biophysics from Columbia University, College of Physicians & Surgeons, New York, and a B.A. in Chemistry with Highest Honors from Clark University, Worcester, Mass. He gained postdoctoral training at the University of Massachusetts Medical School, Worcester, MA in the laboratory of Professor Michael P. Czech.
